Category Archives: Topical Finasteride

Dr. Hasson Ditches Oral Finasteride and Switches to Topical

In 2014, I wrote a post on topical finasteride that has since became one of the most read posts on this blog ever. In hindsight, this is not surprising when considering the fact that I get emails about topical finasteride at least several times a month. People really want to ditch oral finasteride and switch to the topical version in order to reduce their chances of side effects.

Local compounding pharmacies in most cities will be able to make topical finasteride for you if you ask them. However, most of us are eagerly awaiting two thoroughly tested products that could be available for sale worldwide in the near future.

  1. The first of these two is Spanish (previously Swiss) company Polichem’s P-3074 product, which I have covered on this blog several times in the past. European Phase 3 clinical trials for P-3074 are almost completed, while US Phase 3 clinical trials are expected to be completed in May 2018. Moreover, in 2016, an Italian study found the product (when applied to the scalp twice per day) to have superior results to oral finasteride. Several other favorable studies from prior years have also been covered on this blog in the past. P-3074 is vehicled in Hydroxypropyl-Chitosan.
  2. The second of these two products is Canadian hair transplant clinic Hasson & Wong’s topical Finasteride, which is being manufactured in partnership with Italy’s Farmacia Parati. Without this partnership with a well known reputable pharmacy, I would have not put this product in the same category as Polichem’s product. The Hasson & Wong product is a liposomal formulation that has been modified via the attachment of silicone particles to the liposomes.

Perhaps a third company can develop nanoparticle based finasteride delivery in the future?

Dr. Hasson Provides an Update

Since 2014, Dr. Victor Hasson has provided this blog with regular updates about the status of his clinic’s topical finasteride (e.g., see here and here). While Canadian hair loss sufferers have been able to obtain the product from his clinic (and Europeans have been able to access the product via Farmacia Parati), people in other regions of the world including the US have had no such luck. There are a number of regulatory hurdles that Dr. Hasson has been trying to overcome in order to sell in the US.

Last week, Dr. Hasson called me out of the blue and mentioned some new developments, the gist of which are highlighted in the latest blog post on his website. I did not record his call, but below are some highlights that I recollect:

  • Dr. Hasson will answer any intelligent reader questions if you post them in the comments to this post.
  • Hasson & Wong will no longer prescribe oral finasteride and has entirely moved to topical finasteride as their latest blog post mentions.
  • Since February 2017, they have been using their third generation of topical finasteride.
  • Results from topical finasteride (based on analysis of around 800 patients in the Vancouver, BC area over the past several years) have been at least as good as those from oral finasteride.
  • Side effects from topical finasteride have so far been nonexistent.
  • The Hasson & Wong clinic will post a number of updates with patient photos related to this latest development on their website in the coming weeks.
  • US sales should finally become a reality in the near future as Dr. Hasson has selected some pharmacies in the US that will compound his proprietary product.
  • I asked about topical dutasteride (which interests me more than topical finasteride), and Dr. Hasson mentioned that this product is next in line. He talked about some scientific reason that makes the topical dutasteride molecule even more amenable to the scalp and scalp absorption than the topical finasteride molecule. I will ask him to elaborate in the comments to this post.
  • Dr. Hasson mentioned that it has been difficult for him to get his hands on sufficient quantities of dutasteride and therefore their research in that area has lagged. Results from topical dutasteride are superior to those from topical finasteride, as would be expected from what we know about the oral versions of both drugs.

Brief Items of Interest, February 2016

Hair loss news first:

— Thanks to commentator “nosyu” from Japan for posting a link with news from today regarding hair and skin focused Japanese company Adjuvant Cosmetics, the renowned Dr. Takashi Tsuji (RIKEN Center for Developmental Biology) and Organ Technologies getting into some kind of partnership agreement.  The Japanese to English translation did not work well enough for me to gather all the details. Make sure to do a  search on this blog for Dr. Tsuji to read past posts that I have written about him.

— Since I started writing this blog, of all the researchers and companies involved in the hair loss world, Replicel has by far and away provided us with the most regular updates.  This past month has been no exception.  Here is a new video with Replicel’s CEO Lee Buckler starting his presentation at 16:11.  The presentation was part of the Japan External Trade Organization (JETRO)’s “Investing in Japan” conference in Toronto, Canada that took place on January 29th 2016.  The focus of the conference was on Japan’s booming regenerative medicine market.  Lee also discusses Replicel’s partner Shiseido.  From the same conference, here is a pdf of Lee’s presentation.  And finally, here is a new letter from the CEO.

— The latest issue of Nature Biology has an interesting article titled “Biotechs target stagnant baldness market.”  Only half the article is visible for free online, but you can find some hair loss forum threads where people are posting links to the full article.  Some of those links came up with security warnings on my browser, so I am not posting them here.  My favorite and at the same time least favorite sentence from the article:  “It’s been 25 years since Propecia (finasteride), from Merck of Kenilworth, New Jersey, was approved by the US Food and Drug Administration (FDA) in 1992.

— “Hellouser” deserves a financial reward for this stellar effort.

— Study from Japan suggests that COL17A1 (collagen gene) could be a new target for therapy in preventing hair loss.

Kerastem clinical trial page was updated at the end of January 2016.  Go under the locations section of that page to see if there is a clinic near you where you can volunteer.  US only for now it seems.

— I discussed Dr. Rei Ogawa and his surprising mechanotherapy theory on this blog before in 2014.  Now Mr. Ogawa is back again as a co-author of this surprising article on how scalp massage positively impacts dermal papilla cells.  Really hard to believe, but these authors are all respected scientists from a developed country (Japan) with a generally solid reputation insofar as accuracy of research goes.

Excellent new article summarizing latest hair loss treatment options.  One of the co-authors is the famous Dr. Antonella Tosti.

Polichem (which is working on a topical Finasteride product called P-3074) was purchased by Spain’s Almirall.   Also see this new positive study from Italy on P-3074.

— Did Dr. Bernard Arocha just perform the first ever documented ARTAS beard transplant?

Irish men are increasingly opting for hair transplants.  Is a reduction in alcohol consumption next?

And now on to medical items of interest:

Partisanship in the US hurting 21st Century Cures Act.  Thank goodness for Japan, Canada and probably some other countries by now.

— I have discussed Dr. Anthony Atala and the Wake Forest Institute for Regenerative Medicine several times on this blog before.  This week, both were widely covered by the media due to the completion of their 3D bioprinter that can make bone, cartilage and muscle (a culmination of 10 years of work it seems)!  Full journal article here.  No mention about hair in there, but a Canadian team’s 3D bioprinter related article from 2014 mentions the eventual feasibility of adding hair follicles to the new skin.  Some quotes from Dr. Atala here.

UK scientists get gene editing go ahead.  Now western scientists may become less prone to criticize the Chinese too much as they did last year.

Oldest heart transplant recipient dies 33 years after getting a new heart.  Amazing story.  In another article I read, his son said that he died from kidney problems and still had no heart problems.

— If you have older family members that you want to live longer, you might want to try to find a sketchy doctor who can help remove their senescent worn out cells without government approval.  Or ask Liz Parrish for advice on South American clinics.

A major boost for cryonics.

A major boost for cancer treatment.

— This week “New Scientist” had an interesting article titled “First fully approved off-the-shelf stem cells launch in Japan.”  You have to register to read it, so here is the pasted version.